Literature DB >> 31996385

Rare case of acute on chronic hepatic failure in a patient with multiple myeloma-associated amyloidosis.

Muzammil Muhammad Khan1, Mamoon Ur Rashid2, Waqas Ullah3, Ishtiaq Hussain4, Abu Hurairah2.   

Abstract

Amyloidosis is the extracellular deposition of unique protein fibrils in different tissue organs. It is most commonly associated with B-cell malignancy such as multiple myeloma or Waldenstrom macroglobulinaemia. It involves the liver, heart, kidney, peripheral nerves and soft tissues. Liver however is affected, but clinically apparent disease is very rare. Hepatomegaly and mild elevation of alkaline phosphatase is the most common presentation in patients with liver involvement. Acute hepatic failure is a rare presentation with myeloma-induced amyloidosis. The diagnosis can be difficult requiring biopsy or sometimes special staining of the tissue. Management is still very challenging. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gastroenterology; liver disease; oncology

Mesh:

Year:  2020        PMID: 31996385      PMCID: PMC7021185          DOI: 10.1136/bcr-2019-231563

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  22 in total

1.  Disease-free survival following high dose or standard dose therapy in patients with amyloidosis.

Authors:  Patrick J Kiel; Anne O Trueg; Meagan Ferguson; Merrill Benson; Rafat Abonour
Journal:  Br J Haematol       Date:  2015-08-28       Impact factor: 6.998

2.  The role of echocardiography in the non-invasive diagnosis of cardiac amyloidosis.

Authors:  Federico Cacciapuoti
Journal:  J Echocardiogr       Date:  2015-07-14

3.  Treatment of hepatic amyloid light-chain amyloidosis with bortezomib and dexamethasone in a liver transplant patient.

Authors:  Ryosuke Nakano; Masahiro Ohira; Kentaro Ide; Kohei Ishiyama; Tsuyoshi Kobayashi; Hiroyuki Tahara; Hirotaka Tashiro; Yoshiaki Kuroda; Tatsuo Ichinohe; Koji Arihiro; Kazuaki Chayama; Hideki Ohdan
Journal:  Hepatol Res       Date:  2015-01-22       Impact factor: 4.288

4.  A case of prominent hepatic cholestasis developing to hepatic failure in lambda-AL amyloidosis.

Authors:  K Dohmen; M Nagano; R Iwakiri; Y Yamano; Y Kikuchi; M Mizoguchi; Y Iwata; Y Mori; H Ishibashi
Journal:  Gastroenterol Jpn       Date:  1991-06

5.  Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis.

Authors:  K Shiva Kumar; Jay Lefkowitch; Mark W Russo; Charles Hesdorffer; Milan Kinkhabwala; Sandip Kapur; Jean C Emond; Robert S Brown
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

Review 6.  Sinusoidal portal hypertension in hepatic amyloidosis.

Authors:  E Bion; R Brenard; E A Pariente; D Lebrec; C Degott; F Maitre; J P Benhamou
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

7.  The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients.

Authors:  L B Lovat; M R Persey; S Madhoo; M B Pepys; P N Hawkins
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

8.  Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

Authors:  Joseph R Mikhael; Steven R Schuster; Victor H Jimenez-Zepeda; Nancy Bello; Jacy Spong; Craig B Reeder; A Keith Stewart; P Leif Bergsagel; Rafael Fonseca
Journal:  Blood       Date:  2012-02-13       Impact factor: 22.113

9.  Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.

Authors:  Christopher P Venner; Thirusha Lane; Darren Foard; Lisa Rannigan; Simon D J Gibbs; Jennifer H Pinney; Carol J Whelan; Helen J Lachmann; Julian D Gillmore; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Blood       Date:  2012-02-13       Impact factor: 22.113

10.  Poor Outcomes in Hepatic Amyloidosis: A Report of 2 Cases.

Authors:  Brandon Yim; Elizabeth Kertowidjojo; Yue Zhang; Pruthvi Patel
Journal:  Case Rep Oncol Med       Date:  2016-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.